Evidence map›Paper›PMID 27259537›Full record

ArticleVirchows Archiv : an international journal of pathology2016

Somatic mutations in histiocytic sarcoma identified by next generation sequencing.

Qingqing Liu, Keith Tomaszewicz, Lloyd Hutchinson, Jason L Hornick, Bruce Woda, Hongbo Yu

Abstract read
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Qingqing LiuDepartment of Pathology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, USA.
Keith TomaszewiczDepartment of Pathology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, USA.
Lloyd HutchinsonDepartment of Pathology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, USA.
Jason L HornickDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Bruce WodaDepartment of Pathology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, USA.
Hongbo YuDepartment of Pathology, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA, USA. Hongbo.Yu@va.gov.
UMass Memorial Medical Center · USUniversity of Massachusetts Chan Medical School · USBrigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histiocytic sarcoma is a rare malignant neoplasm of presumed hematopoietic origin showing morphologic and immunophenotypic evidence of histiocytic differentiation. Somatic mutation importance in the pathogenesis or disease progression of histiocytic sarcoma was largely unknown. To identify somatic mutations in histiocytic sarcoma, we studied 5 histiocytic sarcomas [3 female and 2 male patients; mean age 54.8 (20-72), anatomic sites include lymph node, uterus, and pleura] and matched normal tissues from each patient as germ line controls. Somatic mutations in 50 "Hotspot" oncogenes and tumor suppressor genes were examined using next generation sequencing. Three (out of five) histiocytic sarcoma cases carried somatic mutations in BRAF. Among them, G464V [variant frequency (VF) of 43.6 %] and G466R (VF of 29.6 %) located at the P loop potentially interfere with the hydrophobic interaction between P and activating loops and ultimately activation of BRAF. Also detected was BRAF somatic mutation N581S (VF of 7.4 %), which was located at the catalytic loop of BRAF kinase domain: its role in modifying kinase activity was unclear. A similar mutational analysis was also performed on nine acute monocytic/monoblastic leukemia cases, which did not identify any BRAF somatic mutations. Our study detected several BRAF mutations in histiocytic sarcomas, which may be important in understanding the tumorigenesis of this rare neoplasm and providing mechanisms for potential therapeutical opportunities.

Indexed as

High-Throughput Nucleotide SequencingMutationAdultAgedDNA Mutational AnalysisFemaleHistiocytic SarcomaHumansImmunophenotypingMaleMiddle AgedOncogenesPolymerase Chain ReactionProto-Oncogene MasProto-Oncogene Proteins B-rafSarcomaMAS1 protein, humanProto-Oncogene MasProto-Oncogene Proteins B-rafBRAF proto-oncogeneHistiocytic sarcomaNext generation sequencingSomatic mutations

Identifiers

PMID27259537
OpenAlexW2410926517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.